Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: warfarin, placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 35 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Infant, Newborn, Diseases, Early Onset Neonatal Sepsis, Early-Onset Meningitis
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment; Dietary Supplement · Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more

Conditions: Bipolar Disorder, Major Depressive Disorder, Menopause
Interventions: Cognitive Behavioral Group Therapy; Behavioral
Lead sponsor: Danette Conklin, PhD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Renal Cell Carcinoma
Interventions: VEGF Trap; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 204
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 148 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 1,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 168
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
Interventions: Erlotinib (tarceva), Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more

Conditions: Renal Cell Carcinoma
Interventions: Tivozanib, Nivolumab; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 36
States / cities: Duarte, California • Irvine, California • La Jolla, California + 31 more

Conditions: Advanced Solid Tumors, Kidney Disease, Renal Impairment
Interventions: AMG 386 + Paclitaxel, AMG 386; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • Lebanon, New Hampshire + 1 more

Conditions: Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions: Brepocitinib PO QD, Placebo PO QD; Drug
Lead sponsor: Priovant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 53
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine, Quetiapine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 25
States / cities: Garden Grove, California • La Mesa, California • San Diego, California + 22 more

Conditions: Peripheral Vascular Disease
Interventions: SUPERA® Nitinol Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 49
States / cities: Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Gastrointestinal Microbiome
Interventions: Hyaluronan; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more

Conditions: Hepatitis C
Interventions: Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Bortezomib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 21
States / cities: Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Bendamustine HCl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Laser photocoagulation; Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Palm Springs, California • Fort Lauderdale, Florida • Fort Myers, Florida + 26 more

Conditions: Lung Cancer
Interventions: laromustine; Drug
Lead sponsor: Vion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • West Haven, Connecticut + 6 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Anatomic Total Shoulder Arthroplasty
Interventions: Anatomic TSA using RTI, Anatomic Total Shoulder Arthroplasty; Device · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Early-Onset Sepsis an NICHD/CDC Surveillance Study

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders

Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Barriers to Peritoneal Dialysis Selection

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Human Pilot Study - HA35 (Hyaluronan Molecular Weight 35) Dietary Supplement for Promoting Intestinal Health

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

The Course of Response to Focal Photocoagulation for DME

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Use of Real Time Instrumentation (RTI) in Total Shoulder Arthroplasty